One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. (Q44865459)
Jump to navigation
Jump to search
scientific article published in May 2004
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. |
scientific article published in May 2004 |
Statements
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes (English)
Kristine B Degn
Claus B Juhl
Grethe Jakobsen
Birgitte Brock
Visvanathan Chandramouli
Joergen Rungby
Bernard R Landau